Acute Myeloid Leukemia
Conditions
Keywords
Acute Myeloid Leukemia
Brief summary
The hypothesis is that the replacement of the standard fludarabine and cytarabine based therapy by azacytidine could result in an improvement of RFS and OS rates in the experimental arm. To fulfill the medical needs in such frail and elderly population, improvements in terms of atileukemic efficacy in the azacytidine experimental arm should be attained without increasing the therapy-related toxicity or decreasing the patients QoL.
Detailed description
This is a multicenter, randomized 1:1, open, and at national level, Phase III clinical trial. This study will be conducted in 3 phases of different duration: 1. Selection phase (up to 14 days from the signature of informed consent): informed consent and review of the inclusion and exclusion criteria performing the relevant assessments. 2. Treatment Phase (from the start of treatment until the end of cycle 9): Induction phase (3 cycles) and consolidation phase (cycles 4-9). Study visits during treatment will be weekly during the induction phase (first 3 cycles) and every 2 weeks until the end of the consolidation phase. 3. Follow-up phase: monthly monitoring will be performed on all patients until they have completed a minimum of 2 years from the start of treatment, whether or not they continue receiving azacitidine cycles or Mini-Fluga according to the protocol. Following these 24 months, follow-up will be carried out at least quarterly. Patients suffering disease progression or relapse of the disease, or being early withdrawn due to any of the reasons specified in the protocol will be followed-up for survival until the end of the study or until the death of all patients, whichever comes first.
Interventions
Sponsors
Dynamic Solutions
PETHEMA Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. \- Having voluntarily given informed consent before performing any test that is not part of routine care of patients. 2. \- Age greater than or equal to 65. 3. \- Morphological diagnosis of non-promyelocytic AML according to the WHO criteria. 4. \- Newly diagnosed AML. 5. \- ECOG performance status \<4. 6. \- Ability and willingness to comply with the schedule of study visits.
Exclusion criteria
1. \- Genetic diagnosis of acute promyelocytic leukemia. 2. \- Patients with AML secondary to myelodysplastic syndrome (MDS) or chronic myeloproloferative syndrome who have been previously treated with antileukemic agents (hypomethylating or standard chemotherapy). Treatment with hydroxyurea prior to randomization is allowed. 3. \- Serum creatinine ≥ 250 mmol / l (≥ 2.5 mg/dL) (unless attributed to AML). 4. \- Bilirubin, alkaline phosphatase or ALT \> 5 times the value of the upper limit of normal (unless attributed to AML) . 5. \- Presence of an active and/or non controlled pathology different to AML which is severe and life-threatening, that in the investigator's opinion, prevents the subject participation in the study. 6. \- Other active concomitant malignancy or whose remission is less than one year from the screening day (except carcinoma in situ). 7. \- Presence of any psychiatric illness or medical condition that, in the investigator's opinion, prevents the subject participation in the study. 8. \- Life expectancy less than X months. 9. \- Inability of the patient or his legal representative to understand and voluntarily sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy (overall survival (OS) attained without increasing the therapy-related toxicity or decreasing the patients QoL. | 4 years | To evaluate the overall survival (OS) in one year treatment with 2 first-line regimens in newly diagnosed elderly patients: 3 cycles of induction chemotherapy based on fludarabine and cytarabine (FLUGA scheme) followed by maintenance with reduced doses(Mini-FLUGA) (standard treatment arm) versus subcutaneous azacitidine cycles (experimental treatment arm). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy (Event free survival (EFS) | 4 years | Event free survival (EFS) |
| Efficacy (Duration of remission.) | 4 years | Duration of remission. |
| Efficacy (Overall survival) Efficcacy | 3 years | Overall survival at 2nd and 3rd year. |
| Safety (Compare hematologic and non-hematologic toxicity) | 3 years | Compare hematologic and non-hematologic toxicity in both arms. |
Countries
Spain
Outcome results
None listed